Welcome to CSNpharm! For Research Use Only!
CCR
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN26541 | ZK756326 dihydrochloride | 1780259-94-0 | ZK-756326 is a potent, selective and non-peptide CCR8 chemokine receptor agonist. ZK 756326 inhibited the binding of the CCR8 ligand I-309 (CCL1), with an IC(50) value of 1.8 muM. ZK 756326 was a full agonist of CCR8, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1. |
| CSN12197 | Vicriviroc maleate | 599179-03-0 | Vicriviroc maleate is a CCR5 antagonist with IC50 of 0.91 nM in clinical development for the treatment of HIV-1. |
| CSN18397 | Vercirnon | 698394-73-9 | Vercirnon is a highly potent antagonist of CCR9, which has been implicated in the aetiology of inflammatory bowel diseases such as Crohns disease. |
| CSN16904 | TAK-220 | 333994-00-6 | TAK-220 is an orally bioavailable small-molecule CCR5 antagonist |
| CSN22613 | SB297006 | 58816-69-6 | SB297006 is a selective antagonist of CCR3 with IC50 of 39 nM |
| CSN12845 | RS 504393 | 300816-15-3 | RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 98 nM and 100 M for inhibition of human recombinant CCR2b and CCR1 receptors respectively). |
| CSN23164 | CCR2 antagonist 4 hydrochloride | 1313730-14-1 | Potent CCR2b antagonist |
| CSN23102 | SB-328437 | 247580-43-4 | Potent and selective CCR3 antagonist |
| CSN28432 | PF-4136309 | 857679-55-1 | PF-4136309 is an orally available CCR2 antagonist with potential immunomodulating and antineoplastic activities. |
| CSN17712 | PF-4136309 | 1341224-83-6 | PF-4136309 is a potent, Selective, and orally bioavailable CCR2 antagonist. |
| CSN26607 | PF-04634817 succinate | 2140301-98-8 | PF-0463481 succinate is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC50=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC50=470 nM). PF-0463481 succinate is safe and well-tolerated and has the potential for the study of diabetic nephropathy[3]. |
| CSN17807 | NSC5844 | 140926-75-6 | NSC 5844 is a bisquinoline compound with C-C chemokine receptor type 1 CCR1-agonistic properties |
| CSN18995 | MK-0812 Succinate | 851916-42-2 | MK-0812 succinate is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes |
| CSN13664 | MK-0812 | 624733-88-6 | MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes. |
| CSN11361 | Maraviroc | 376348-65-1 | Maraviroc is a selective CCR5 antagonist (IC50 6.4 nM) and displays potent anti-HIV-1 activity. |
| CSN27647 | K777 | 233277-99-1 | K777 is an irreversible inhibitor of cysteine protease inhibitor and a antagonist of CCR4. |
| CSN17640 | INCB3344 | 1262238-11-8 | INCB3344 is a potent and selective small molecule antagonist of the mouse CCR2 receptor and inhibits the binding of CCL2 to mouse monocytes with nanomolar potency (IC50 10 nM). |
| CSN13799 | INCB 3284 dimesylate | 887401-93-6 | INCB 3284 is a potent, selective and orally bioavailable hCCR2 antagonist with IC50 of 3.7 nM. |
| CSN18528 | INCB 3284 | 887401-92-5 | INCB 3284 is a potent, selective and orally bioavailable hCCR2 antagonist with IC50 of 3.7 nM (inhibition of monocyte chemoattractant protein-1 binding to hCCR2). |
| CSN22186 | GW 766994 | 408303-43-5 | GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis. |
| CSN22234 | GSK2239633A | 1240516-71-5 | GSK2239633A is a CC-chemokine receptor 4 CCR4 antagonist which inhibits the binding of 125I-TARC to human CCR4 with a pIC50 of 796011 |
| CSN23233 | DAPTA | 106362-34-9 | DAPTA is a potent and selective CCR5 antagonist |
| CSN26606 | Cenicriviroc Mesylate | 497223-28-6 | Cenicriviroc, also known as TAK-652 and TBR-652, is an experimental drug candidate for the treatment of HIV infection. It is being developed by Takeda Pharmaceutical and Tobira Therapeutics. Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. Inhibition of CCR2 may have an anti-inflammatory effect. |
| CSN15987 | Cenicriviroc | 497223-25-3 | Cenicriviroc is an oral, dual CCR2CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity. |
| CSN22732 | C-021 dihydrochloride | 1784252-84-1 | C 021 2HCl is a potent CCR4 chemokine receptor antagonist. |
| CSN18114 | BX471 | 217645-70-0 | BX471 is a potent, selective non-peptide CCR1 antagonist (Ki 1 nM for human CCR1) and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. |
| CSN18182 | BX471 hydrochloride | 288262-96-4 | BX471 HCl is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1) and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. |
| CSN22720 | BMS CCR2 22 | 445479-97-0 | BMS CCR2 22 is a high affinity CCR2 chemokine receptor antagonist with IC50 of 5.1 nM. |
| CSN20665 | AZD2098 | 566203-88-1 | AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor, used for asthma research. |
| CSN20666 | AZD-1678 | 942137-41-9 | AZD1678 is a potent CC-chemokine receptor 4 (CCR4) inhibitor, used for asthma research. |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
